Search Results
19 results found-
Share buy-backs were undertaken at higher prices than the original subscription prices which reduced the historical balance for ordinary share contributed equity to nil.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
Closing balance 195.1 168.2 29.1 126.0 224.2 294.2 Due to share buy-backs being undertaken at higher prices than the original subscription prices, the balance for ordinary share contributed equity has been reduced to nil, and a reserve created to reflect the excess value of Nature and purpose of reserves shares bought over the original amount of subscribed capital.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
Nature and purpose of reserves Due to share buy-backs being undertaken at higher prices i. Share-based payments reserve than the original subscription prices, the balance for ordinary The share-based payments reserve is used to recognise the share contributed equity has been reduced to nil, and a reserve fair value of options, performance rights and GESP rights created to reflect the excess value of shares bought over the issued to employees.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf -
i. Share-based payments reserve Due to share buy-backs being undertaken at higher prices than The share-based payments reserve is used to recognise the the original subscription prices, the balance for ordinary share fair value of options, performance rights and GESP rights contributed equity has been reduced to nil, and a reserve created issued to employees.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2016-full.pdf -
e) participation in, acceptance of, or trading under, an offer or invitation made to all or most security holders such as a rights issue, a security purchase plan, CSL's Distribution Reinvestment Plan and an equal access buy back (
https://www.csl.com/-/media/shared/documents/one-csl/csl-governance-docs/securities-dealing-policy.pdf -
GESP, including details of shares issued under the scheme, is set Due to share buy-backs being undertaken at higher prices than out in Note 5.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
and GESP, including details of shares issued under the scheme, Due to share buy-backs being undertaken at higher prices is set out in Note 5.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
When people interact with things, like medical devices, almost anything can happen, CSL’s Monica Tavanti says. That’s why human factors research plays a key role in developing products.
https://www.csl.com/we-are-csl/vita-original-stories/2022/the-human-factor -
ZEMAIRA®/RESPREEZA® (Alpha 1 Antitrypsin) AAT Deficiency Garadacimab (Anti-FXIIa mAb) Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis Trabikibart (Anti-Beta Common mAb) Asthma CSL787 (Nebulised Ig) Non-Cystic Fibrosis Bronchiectasis
https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2021-22.pdf